We pinpoint the dLED characteristic of the NRAS gene, meaning that if a tumor has NRAS mutated a treatment that targets NRAS itself would be the best option to reduce their tumorigenicity, whereas if it is NRAS wild-type, a PTPN11 inhibition would be a better recommendation. This evidence concerns the gene NRAS and neoplasm.